|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3713 USD | +0.76% |
|
+3.43% | -72.29% |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
| 05-28 | Soligenix - increases maximum offering under sales agreement by $2.96 million | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLIGENIX, INC. | Bio Therapeutic Drugs | +0.76% | +3.43% | -72.29% | -71.87% | -99.84% | 5.5M |  |  | |
- Stock Market
- Stocks
- SNGX Stock
- Charts Soligenix, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
